Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01072695 | Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection | PHASE2 | COMPLETED | 46 | — | — | Feb 1, 2010 | Jan 1, 2012 | May 31, 2012 | 12 | Belgium, France +2 |
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GS-9256 | DRUG | 75 mg BID x 28 days |
| GS-9190 | DRUG | 40 mg BID x 28 days |
| Ribavirin | DRUG | 1000-1200 mg/day given BID |
| Peginterferon alfa-2a | DRUG | 180 ug q week |
Inclusion Criteria: * Adult subjects, ages 18-70 * Willing able to provide informed consent * BMI between 18 and 36 kg/m2 (inclusive) * Chronic HCV infection, genotype 1 * HCV RNA \>/= 3 log, but \< 7.2 log10 IU/ml at screen * Liver biopsy, FibroTest, or FibroScan indicating absence of cirrhosis * ...